Amgen has completed its $27.8-billion acquisition of Horizon Therapeutics. The acquisition was announced in December 2022, and was sued by the FTC to block it in May 2023. 

Horizon has 12 marketed medicines and a pipeline with more than 20 development programs. Its top commercial product is Tepezza (teprotumumab-trbw), a drug for treating thyroid eye disease, which 2021 sales of $1.66 billion. Its second best-selling product is Krystexxa (pegloticase), a drug for treating gout, which had 2021 sales of $565 million. The company has more than 2,000 employees.   

Under the agreement, Amgen paid $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion. 

Source: Amgen